Articles From: CyrusOne’s Josh Snowhorn Elected to Open-IX Board of Directors to CytRx Launches Discovery Laboratory to Develop Albumin-Binding Anti-Cancer Drug Platform


Global data center provider CyrusOne (NASDAQ: CONE) is pleased to announce that Josh Snowhorn , CyrusOne vice president and general manager, interconnection, has been elected to the Open-IX Association’s board of directors.
Sign-up for CyrusOne’s Josh Snowhorn Elected to Open-IX Board of Directors investment picks
Global data center provider CyrusOne (NASDAQ: CONE) announced today that its Chief Commercial Officer Tesh Durvasula and Vice President and General Manager of Interconnection Josh Snowhorn are both expected to participate in panels at DataCenter Dynamics Converge at the Renaissance Dallas Richardson Hotel on Tuesday, Dec.
Sign-up for CyrusOne’s Tesh Durvasula and Josh Snowhorn to Speak at DataCenter Dynamics Converge Dallas investment picks
CYS Investments, Inc. (NYSE: CYS) (the "Company") today announced that it will host a conference call at 9:00 AM Eastern Time on Tuesday, October 21, 2014, to discuss its financial results for the quarter ended September 30, 2014.
Sign-up for CYS Investments, Inc. Announces Conference Call to Discuss Third Quarter 2014 Results investment picks
CYS Investments, Inc. (NYSE: CYS) (“CYS”, "we", "our", or the “Company”) today announced financial results for the quarter ended September 30, 2014.
Sign-up for CYS Investments, Inc. Announces Third Quarter 2014 Financial Results investment picks
The Board of Directors of CYS Investments, Inc. (NYSE: CYS) (the “Company”) today declared a quarterly dividend of $0.30 per share of common stock for the fourth quarter of 2014.
Sign-up for CYS Investments, Inc. Board of Directors Declares Fourth Quarter 2014 Common Stock Dividend of $0.30 Per Share, and Preferred Stock Dividends investment picks
CYS Investments, Inc. (NYSE: CYS) ("CYS" or the "Company") today announced that Kevin E.
Sign-up for CYS Investments, Inc. to Present at Bank of America Merrill Lynch 2014 Banking & Financial Services Conference investment picks
Cytori Therapeutics, Inc. (NASDAQ: CYTX) today reported positive results from a clinical study of Cytori Cell Therapy™ in anterior cruciate ligament (ACL) reconstruction of patients with ACL tears.
Sign-up for Cytori Announces Promising Results in a Feasibility Trial of Cytori Cell Therapy in Conjunction with Anterior Cruciate Ligament Repair investment picks
Cytori Therapeutics (NASDAQ: CYTX) today announced its updated strategy and plan to restructure its operations and reduce costs.
Sign-up for Cytori Consolidates and Restructures Its Operations, Provides Business Update investment picks
Cytori Therapeutics, Inc. (NASDAQ: CYTX) today confirmed that two Japanese regenerative medicine laws, which went into effect on November 25, 2014, remove regulatory uncertainties and provide a clear path for the Company to commercialize and market Cytori Cell Therapy™ and its Celution® System under the Company’s existing and planned regulatory approvals.
Sign-up for Cytori Expects New Japan Laws to Boost Adoption of Cytori Cell Therapy investment picks
Cytori Therapeutics (NASDAQ: CYTX) today reports its third quarter 2014 financial results and provides updates on clinical development and commercialization activities.
Sign-up for Cytori Reports Third Quarter 2014 Business and Financial Results investment picks
Cytori Therapeutics, Inc. (NASDAQ: CYTX) has been selected to participate in a U.S. trade mission to Japan and South Korea led by the U.S. Secretary of Commerce Penny Pritzker.
Sign-up for Cytori Therapeutics Invited to Participate in Trade Mission to Asia with U.S. Secretary of Commerce investment picks
Cytori Therapeutics, Inc. (NASDAQ: CYTX) has received notification from the FDA that Cytori has provided additional information sufficient to support continuation of enrollment in its ATHENA cardiovascular trials.
Sign-up for Cytori Therapeutics Receives FDA Approval to Resume ATHENA Trial Enrollment investment picks
Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast Company invites individual and institutional investors as well as advisors to attend and ask questions at VirtualInvestorConferences.com Canada NewsWire NEW YORK and SAN DIEGO , Nov.
Sign-up for Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast investment picks
Company invites individual and institutional investors as well as advisors to attend and ask questions at VirtualInvestorConferences.com NEW YORK and SAN DIEGO , Nov.
Sign-up for Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast investment picks
Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that it has completed the previously announced sale of shares of its Series A 3.6% convertible preferred stock pursuant to a registered direct offering representing gross proceeds of approximately $13.5 million.
Sign-up for Cytori Therapeutics, Inc. Announces Closing of Financing investment picks
The Board of Directors of Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that Lloyd H.
Sign-up for Cytori Therapeutics, Inc. Announces Resignation of Lloyd H. Dean Effective November 1, 2014 investment picks
Cytori Therapeutics, Inc. (NASDAQ: CYTX) entered into a definitive securities purchase agreements to raise an aggregate of $13.5 million in a registered direct offering, with net proceeds estimated to be approximately $12.5 million, after deducting placement agent fees and estimated offering expenses.
Sign-up for Cytori Therapeutics, Inc. to Raise $13.5 Million in Registered Direct Offering investment picks
Cytori Therapeutics' Investor Presentation Now Available for On-Demand Viewing Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation Canada NewsWire NEW YORK and SAN DIEGO , Dec.
Sign-up for Cytori Therapeutics' Investor Presentation Now Available for On-Demand Viewing investment picks
Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation NEW YORK and SAN DIEGO , Dec.
Sign-up for Cytori Therapeutics' Investor Presentation Now Available for On-Demand Viewing investment picks
Cytori Therapeutics (NASDAQ: CYTX) will provide a live webcast of its third quarter financial results and business update on Thursday, November 6, 2014 at 5:30 PM Eastern Time.
Sign-up for Cytori to Webcast Third Quarter Financial Results on November 6 investment picks
LOS ANGELES , Oct.
Sign-up for CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium investment picks
All Currently Enrolled Patients Can Continue Receiving Aldoxorubicin Therapy or Comparator Drugs; One Inclusion/Exclusion Criteria to be Amended for New Trial Patients to Add Additional Safety Measure Company Expects Trial Timelines to Remain Materially Unchanged LOS ANGELES , Nov.
Sign-up for CytRx Announces Partial Clinical Hold Affecting Aldoxorubicin Clinical Trials investment picks
LOS ANGELES , Oct.
Sign-up for CytRx Announces Publication of Preclinical Glioblastoma Data in Neoplasia investment picks
LOS ANGELES , Oct.
Sign-up for CytRx Announces Unexpected Passing of Chairman Max Link, PhD investment picks
LOS ANGELES , Oct.
Sign-up for CytRx Appoints Steven A. Kriegsman as Chairman of the Board investment picks
Completion of Enrollment Expected in 2015; Progression-Free Survival Data Expected in mid-2016 LOS ANGELES , Sept.
Sign-up for CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer investment picks
Expected to Yield First Clinical Candidate in 2015 LOS ANGELES , Oct.
Sign-up for CytRx Launches Discovery Laboratory to Develop Albumin-Binding Anti-Cancer Drug Platform investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: CyrusOne’s Josh Snowhorn Elected to Open-IX Board of Directors to CytRx Launches Discovery Laboratory to Develop Albumin-Binding Anti-Cancer Drug Platform
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent